Gene therapy using reelin fragments in mouse brain - there is a considerable need for both disease modifying and symptomatic alzheimer's disease (ad) treatments

Active Grant Awarded

Award ID
R01AG094132
Recipient
Awarding agency
Obligated
$654,111

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
East Lansing, MI 48824, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded Michigan State University, doing business as Henry Ford Health+Michigan State University Health Sciences, $654,111 on September 17, 2026, under the Aging Research program (CFDA 93.866) via Grant R01AG094132. The grant's stated mission is to support research and training on the aging process, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.

The project evaluates the feasibility of gene therapy using the reelin (RELN) protein as a route toward clinical trials in Alzheimer's disease. Because the full-length RELN sequence is too large to package into FDA-approved recombinant adeno-associated virus (AAV) vectors, the team has developed AAV-packagable RELN fragments that signal through the canonical RELN receptors. Those fragments reportedly rescued memory deficiencies in mice with reduced RELN and in mice with developmental-defect mutations.

Obligated funding is $654,111, with an ultimate completion date of June 30, 2031. Work is performed in East Lansing, Michigan 48824.

Description

The primary goal of this project is to evaluate the feasibility of gene therapy with the protein reelin (RELN) for translation to clinical trials in ad. The RELN protein, which is deleted in the reeler mutant mouse, is a large, secreted extracellular matrix protein that migrates at 450KD on page gels. RELN signaling in neurons occurs through the receptors vldlr and APOER2, which also bind and internalize apolipoprotein E. Recently, lopera (2023) reported that a specific RELN variant H3447A (COLBOS) is associated with delayed penetrance of symptoms in a carrier of the familial ad presenilin 1 mutation found in the columbian kindred. The authors suggest the mutation provides a gain in function that enhances RELN signaling. A gwas analysis of APOE4 homozygotes identified variants of DAB1, an adapter protein phosphorylated in response to RELN receptor signaling, as a 2.3 fold risk factor for ad. RELN neurons are lost early in ad and the most vulnerable neuronal subtypes at early braak stages are those expressing RELN receptors. Supplementation with RELN protein can enhance learning and long term potentiation. In a variety of mouse models with impaired cognition, intracranial injections of RELN protein show short term benefits, but this route is unlikely to become a viable treatment for people living with or at risk for ad. While gene therapy would be a stable delivery platform, the full-length nucleotide sequence is too large to package into the FDA approved recombinant adeno-associated virus (AAV) vectors. Fragments of RELN are capable of signaling through the canonical RELN receptors. Members of this team have developed AAV-packagable RELN fragments that are effective in rescuing memory deficiencies in mice with reduced RELN and mutations causing developmental defects. Our team has also developed a new mouse model of amyloid-enhanced tauopathy, combining an APP mouse line and intravenous injections brain penetrant AAV vectors expressing human TAU. Aim 1 proposes the hypothesis that overexpression of an active RELN fragment will reduce the amyloid enhanced tauopathy phenotype. Our preliminary data indicate that the RELN treatment rescues memory impairments in the reduces insoluble AΒ. Aim 2 will compare the signaling activity of multiple RELN fragments with and without the COLBOS mutation in a 3 screen funnel examining receptor clustering, activity in primary neurons and activity in mice haplo-insufficient for RELN. Preliminary data finds the COLBOS mutation increases APOER2 clustering, the first screening step. Aim 3 will test the effects of RELN constructs with and without the COLBOS mutation in the amyloid-enhanced tauopathy model. Aim 4 will perform single nuclei transcriptomic analysis to identify pathways and potential downstream targets that are associated with enhanced RELN signaling. The results of these studies will inform whether gene therapy to enhance RELN signaling as a treatment for dementia should be pursued, and at what stages of ad the therapy can be tested clinically.

Quick answers

Who received award R01AG094132?

R01AG094132 was awarded to Michigan State University by National Institute on Aging (National Institutes of Health) on September 17, 2026.

How much is award R01AG094132 worth?

$654,111 has been obligated on R01AG094132.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award